Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage
biopharmaceutical company focused on the discovery, development,
and commercialization of novel treatments for patients suffering
from serious hematologic diseases, today announced the appointment
of Pamela Stephenson, MPH as the company’s Chief Commercial
Officer. Ms. Stephenson is an experienced biotech executive with
significant expertise in commercial and strategic leadership,
particularly in therapies for rare diseases, and will be
responsible for all aspects of Disc’s global commercialization
strategy and execution.
“We are delighted to welcome an accomplished leader such as
Pamela to Disc, where her breadth of commercial experience and
acumen will be instrumental as the company continues to grow,” said
John Quisel, J.D., Ph.D., President and Chief Executive Officer of
Disc. “Pamela’s track record of building and executing successful
global commercial launches, particularly for rare disease markets,
comes at an opportune time for Disc as we enter late-stage
development and begin commercial planning and engaging key
stakeholders.”
“I am excited to be joining Disc at this pivotal time in the
company’s trajectory towards building a leading hematology company.
Disc’s assets have the potential to make a significant impact on
the lives of patients, with compelling value propositions and
meaningful market opportunities,” said Ms. Stephenson. “With
significant milestones this year for all three pipeline programs, I
look forward to leading the commercialization efforts to support
Disc’s mission of delivering novel treatments to patients with high
unmet need.”
Ms. Stephenson has more than 25 years of biopharma commercial
leadership experience across multiple functions and disease areas.
Most recently, she served as the Chief Commercial Officer of
Albireo, which was acquired by Ipsen, spearheading the successful
launch of Bylvay for a rare cholestatic liver disease. Before
joining Albireo, Ms. Stephenson served as Vice President, Global
Market Access and Value, at Vertex Pharmaceuticals, where she led
the global market access and pricing strategy for current and
future products. Earlier in her tenure at Vertex, she led marketing
and sales activities for the company’s hepatitis C and cystic
fibrosis lines of business, and oversaw the U.S. launches of
Incivek® (telaprevir) and Orkambi® (lumacaftor/ivacaftor). Prior to
Vertex, Ms. Stephenson spent 10 years at Pfizer in marketing roles
of increasing responsibility for brands such as Viagra® (sildenafil
citrate), Lyrica® (pregabalin), and Aromasin® (exemestane). Ms.
Stephenson served as board member of Zynerba Pharmaceuticals, a
public biotech company focused on developing therapeutics for
patients with rare neuropsychiatric conditions, which was acquired
by Harmony Biosciences in October 2023. Ms. Stephenson holds a
bachelor’s degree from Brown University and received her master’s
degree in public health from Boston University School of Public
Health.
In connection with Ms. Stephenson’s appointment, Disc granted to
Ms. Stephenson an inducement equity award outside of Disc’s Amended
and Restated 2021 Stock Option and Incentive Plan in accordance
with NASDAQ Listing Rule 5635(c)(4), comprised of (i) an option to
purchase 55,000 shares (the “Option Award”) of Disc’s common stock
(“Common Stock”), at an exercise price equal to the closing price
of the Common Stock on the date of grant, and (ii) a restricted
stock unit award for 36,666 shares of Common Stock (the “RSU Award”
and, together with the Option Award, the “Inducement Award”). The
Option Award shall vest 25% on the first anniversary of Ms.
Stephenson’s start date, with the remainder vesting in 36 equal
monthly installments thereafter. The RSU Award shall vest in equal
installments on each of the first, second, third, and fourth
anniversaries of the vesting date set by Disc’s company vesting
policy. The Inducement Award was approved by Disc’s Board of
Directors (the “Board”), including a majority of the independent
directors serving on the Board.
About Disc Medicine
Disc Medicine (NASDAQ:IRON) is a clinical-stage
biopharmaceutical company committed to discovering, developing, and
commercializing novel treatments for patients who suffer from
serious hematologic diseases. We are building a portfolio of
innovative, potentially first-in-class therapeutic candidates that
aim to address a wide spectrum of hematologic diseases by targeting
fundamental biological pathways of red blood cell biology,
specifically heme biosynthesis and iron homeostasis. For more
information, please visit www.discmedicine.com.
Disc Cautionary Statement Regarding Forward-Looking
Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, express or implied statements
regarding Disc’s expectations with respect to the chief commercial
officer position, data read-outs, and Disc’s development and
commercialization. The use of words such as, but not limited to,
“believe,” “expect,” “estimate,” “project,” “intend,” “future,”
“potential,” “look forward,” “continue,” “may,” “might,” “plan,”
“will,” “should,” “seek,” “anticipate,” or “could” or the negative
of these terms and other similar words or expressions that are
intended to identify forward-looking statements. Forward-looking
statements are neither historical facts nor assurances of future
performance. Instead, they are based on Disc’s current beliefs,
expectations and assumptions regarding the future of Disc’s
business, future plans and strategies, clinical results and other
future conditions. New risks and uncertainties may emerge from time
to time, and it is not possible to predict all risks and
uncertainties. No representations or warranties (expressed or
implied) are made about the accuracy of any such forward-looking
statements.
Disc may not actually achieve the plans, intentions or
expectations disclosed in these forward-looking statements, and
investors should not place undue reliance on these forward-looking
statements. Actual results or events could differ materially from
the plans, intentions and expectations disclosed in the
forward-looking statements as a result of a number of material
risks and uncertainties including but not limited to: Disc’s
expectations regarding the chief commercial officer position;
Disc’s expectations regarding leadership, future growth and
innovation; Disc’s expectations regarding the milestones for its
research and development programs in 2024; Disc’s expectations of
entering late-stage development and planning for commercialization;
and the other risks and uncertainties described in the “Risk
Factors” section of our Annual Report on Form 10-K for the year
ended December 31, 2022, Quarterly Reports on Form 10-Q for the
quarters ended March 31, 2023, June 30, 2023, and September 30,
2023 and other documents filed by Disc from time to time with the
Securities and Exchange Commission (SEC), as well as discussions of
potential risks, uncertainties, and other important factors in
Disc’s subsequent filings with the SEC. Any forward-looking
statement speaks only as of the date on which it was made. None of
Disc, nor its affiliates, advisors or representatives, undertake
any obligation to publicly update or revise any forward-looking
statement, whether as result of new information, future events or
otherwise, except as required by law.
Media Contact
Peg RusconiVerge Scientific
Communicationsprusconi@vergescientific.com
Investor Relations Contact
Christina TartagliaStern Investor
Relationschristina.tartaglia@sternir.com
Disc Medicine (NASDAQ:IRON)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Disc Medicine (NASDAQ:IRON)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024